Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Analysis for Alpha-Pyrrolidinovalerophenone and its 2-oxo-PVP Metabolite in Plasma by LiquidChromatography-Tandem Mass Spectrometry.

Andrenyak DM, Moody DE, Crites JM, Baumann MH.

J Anal Toxicol. 2019 Nov 27. pii: bkz096. doi: 10.1093/jat/bkz096. [Epub ahead of print]

PMID:
31776563
2.

Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?

Liu T, Lewis TR, Moore JN, Kraft WK, Gauda EB, Sartori D, Moody DE, Gobburu JVS, Ivaturi V.

CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):469-477. doi: 10.1002/psp4.12407. Epub 2019 May 10.

3.

The inhibition of first-pass metabolism of ethanol by H2-receptor antagonists: a tabulated review.

Moody DE.

Expert Opin Drug Saf. 2018 Sep;17(9):917-934. doi: 10.1080/14740338.2018.1512969. Review.

PMID:
30117350
4.

Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.

Briones M, Shoptaw S, Cook R, Worley M, Swanson AN, Moody DE, Fang WB, Tsuang J, Furst B, Heinzerling K.

Drug Alcohol Depend. 2018 Aug 1;189:30-36. doi: 10.1016/j.drugalcdep.2018.04.023. Epub 2018 May 25.

5.

The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.

Moore JN, Gastonguay MR, Ng CM, Adeniyi-Jones SC, Moody DE, Fang WB, Ehrlich ME, Kraft WK.

Clin Pharmacol Ther. 2018 Jun;103(6):1029-1037. doi: 10.1002/cpt.1064. Epub 2018 Apr 28.

6.

Inhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants.

Moody DE, Fu Y, Fang WB.

Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):327-334. doi: 10.1111/bcpt.12999. Epub 2018 Apr 19.

7.

Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Andrenyak DM, Moody DE, Slawson MH, O'Leary DS, Haney M.

J Anal Toxicol. 2017 May 1;41(4):277-288. doi: 10.1093/jat/bkw136.

8.

Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Grasing K, Mathur D, DeSouza C, Newton TF, Moody DE, Sturgill M.

Am J Addict. 2016 Aug;25(5):392-9. doi: 10.1111/ajad.12402. Epub 2016 Jul 8.

9.

Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.

DeYoung DZ, Heinzerling KG, Swanson AN, Tsuang J, Furst BA, Yi Y, Wu YN, Moody DE, Andrenyak DM, Shoptaw SJ.

J Clin Psychopharmacol. 2016 Aug;36(4):347-54. doi: 10.1097/JCP.0000000000000511.

10.

Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK.

Pharmacotherapy. 2015 Jul;35(7):670-80. doi: 10.1002/phar.1610. Epub 2015 Jul 14.

11.

Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids.

Christodoulides N, De La Garza R 2nd, Simmons GW, McRae MP, Wong J, Newton TF, Smith R, Mahoney JJ III, Hohenstein J, Gomez S, Floriano PN, Talavera H, Sloan DJ, Moody DE, Andrenyak DM, Kosten TR, Haque A, McDevitt JT.

Drug Alcohol Depend. 2015 Aug 1;153:306-13. doi: 10.1016/j.drugalcdep.2015.04.026. Epub 2015 May 22.

12.

A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study.

Carlquist JF, Moody DE, Knight S, Johnson EG, Fang WB, Huntinghouse JA, Rollo JS, Webster LR, Anderson JL.

Mol Diagn Ther. 2015 Apr;19(2):131-8. doi: 10.1007/s40291-015-0137-4.

PMID:
25903311
13.

Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

Moody DE, Liu F, Fang WB.

J Anal Toxicol. 2015 Jun;39(5):374-86. doi: 10.1093/jat/bkv030. Epub 2015 Apr 12.

PMID:
25868557
14.

The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.

Tetrault JM, McCance-Katz EF, Moody DE, Fiellin DA, Lruie BS, DInh AT, Fiellin LE.

J Subst Abuse Treat. 2015 Apr;51:70-4. doi: 10.1016/j.jsat.2014.10.010. Epub 2014 Nov 5.

PMID:
25480096
15.

Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine.

Hicks MJ, Kaminsky SM, De BP, Rosenberg JB, Evans SM, Foltin RW, Andrenyak DM, Moody DE, Koob GF, Janda KD, Ricart Arbona RJ, Lepherd ML, Crystal RG.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):40-9. doi: 10.1089/humc.2013.231.

16.

Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.

Masson CL, Rainey PM, Moody DE, McCance-Katz EF.

Am J Addict. 2014 Jan-Feb;23(1):34-40. doi: 10.1111/j.1521-0391.2013.12052.x. Epub 2013 Jun 10.

17.

In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.

Moody DE, Liu F, Fang WB.

J Anal Toxicol. 2013 Oct;37(8):476-85. doi: 10.1093/jat/bkt060. Epub 2013 Jul 14.

PMID:
23857299
18.
19.

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH.

Expert Rev Clin Pharmacol. 2013 May;6(3):249-69. doi: 10.1586/ecp.13.18. Review.

20.

Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Nunamaker EA, Halliday LC, Moody DE, Fang WB, Lindeblad M, Fortman JD.

J Am Assoc Lab Anim Sci. 2013 Jan;52(1):48-56.

21.

Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.

Moody DE.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):675-97. doi: 10.1517/17425255.2013.783567. Epub 2013 Mar 29. Review.

PMID:
23537174
22.

Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.

Douglas Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):80-5. doi: 10.3109/00952990.2013.764885.

PMID:
23421567
23.

Formulation of buprenorphine for sublingual use in neonates.

Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK.

J Pediatr Pharmacol Ther. 2011 Oct;16(4):281-4. doi: 10.5863/1551-6776-16.4.281.

24.

Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry.

McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE.

J Anal Toxicol. 2012 Mar;36(2):81-7. doi: 10.1093/jat/bkr020.

PMID:
22337776
25.

Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

Gruber VA, Rainey PM, Moody DE, Morse GD, Ma Q, Prathikanti S, Pade PA, Alvanzo AA, McCance-Katz EF.

Clin Infect Dis. 2012 Feb 1;54(3):414-23. doi: 10.1093/cid/cir799. Epub 2011 Nov 18.

26.

Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL.

J Clin Pharmacol. 2012 Apr;52(4):600-6. doi: 10.1177/0091270011401620. Epub 2011 May 24. No abstract available.

27.

Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):326-34. doi: 10.1016/j.drugalcdep.2011.04.013. Epub 2011 May 19.

28.

Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Moody DE, Fang WB, Morrison J, McCance-Katz E.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.

29.

Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH.

Am J Drug Alcohol Abuse. 2011 Jul;37(4):224-8. doi: 10.3109/00952990.2011.568081. Epub 2011 Mar 28.

PMID:
21438849
30.

The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL.

Addiction. 2011 Aug;106(8):1460-73. doi: 10.1111/j.1360-0443.2011.03424.x. Epub 2011 May 3.

31.

Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Chang Y, Fang WB, Lin SN, Moody DE.

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):55-62. doi: 10.1111/j.1742-7843.2010.00628.x. Epub 2010 Sep 2.

32.

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4.

33.

Effect of cocaine use on buprenorphine pharmacokinetics in humans.

McCance-Katz EF, Rainey PM, Moody DE.

Am J Addict. 2010 Jan-Feb;19(1):38-46. doi: 10.1111/j.1521-0391.2009.00001.x.

PMID:
20132120
34.

Lack of clinically significant drug interactions between nevirapine and buprenorphine.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM.

Am J Addict. 2010 Jan-Feb;19(1):30-7. doi: 10.1111/j.1521-0391.2009.00006.x.

35.

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF.

Am J Addict. 2010 Jan-Feb;19(1):17-29. doi: 10.1111/j.1521-0391.2009.00004.x.

36.
37.

Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.

Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ.

Drug Metab Dispos. 2009 Dec;37(12):2323-9. doi: 10.1124/dmd.109.028605. Epub 2009 Sep 22.

38.

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.

39.

The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.

De La Garza R 2nd, Zorick T, Heinzerling KG, Nusinowitz S, London ED, Shoptaw S, Moody DE, Newton TF.

Pharmacol Biochem Behav. 2009 Nov;94(1):186-93. doi: 10.1016/j.pbb.2009.08.007. Epub 2009 Aug 19.

40.

A liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitation of aripiprazole in human plasma.

Lin SN, Lamm L, Newton TF, Reid MS, Moody DE, Foltz R.

J Anal Toxicol. 2009 Jun;33(5):237-42.

PMID:
19671242
41.

Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics.

Walsh SL, Stoops WW, Moody DE, Lin SN, Bigelow GE.

Exp Clin Psychopharmacol. 2009 Aug;17(4):205-16. doi: 10.1037/a0016469.

42.
43.

The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

Moody DE, Chang Y, Huang W, McCance-Katz EF.

Basic Clin Pharmacol Toxicol. 2009 Sep;105(3):211-5. doi: 10.1111/j.1742-7843.2009.00432.x. Epub 2009 Jun 4.

44.

Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME.

Pediatrics. 2008 Sep;122(3):e601-7. doi: 10.1542/peds.2008-0571. Epub 2008 Aug 11.

45.

Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs.

Abbo LA, Ko JC, Maxwell LK, Galinsky RE, Moody DE, Johnson BM, Fang WB.

Vet Ther. 2008 Summer;9(2):83-93.

PMID:
18597246
46.
47.

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM.

Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. Epub 2007 Jul 23.

48.

Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing.

Compton P, Ling W, Chiang CN, Moody DE, Huber A, Ling D, Charuvastra C.

J Addict Med. 2007 Jun;1(2):88-95. doi: 10.1097/ADM.0b013e31806dcc3e.

PMID:
21768940
49.

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD.

J Pharm Biomed Anal. 2007 May 9;44(1):188-95. Epub 2007 Feb 16.

PMID:
17391891
50.

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S235-46.

PMID:
17109310

Supplemental Content

Loading ...
Support Center